financetom
Business
financetom
/
Business
/
Italy working on alternative to Musk's Starlink, minister says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Italy working on alternative to Musk's Starlink, minister says
Feb 19, 2025 8:45 AM

ROME (Reuters) - Italy is aiming to develop its own low-orbit satellites for government communications, its industry minister said on Wednesday, presenting it as an alternative to systems provided by U.S. billionaire Elon Musk.

Prime Minister Giorgia Meloni's government had previously said it was considering the use of Musk's Starlink satellites to provide encrypted communications between officials operating in risky areas.

The suggestion was sharply criticised by opposition politicians, who questioned the wisdom of handing a national security contract to a foreign entrepreneur who is also part of the U.S. government under President Donald Trump.

"We are in fact working on the creation of a national low-orbit satellite system developed independently, with the involvement of the main national players," Minister Adolfo Urso said in the lower house of parliament.

Urso, a member of Meloni's right-wing Brothers of Italy party, said that would offer a competitive alternative to infrastructure provided by other global operators, including Musk.

Urso did not give a timing for the development of the project and did not specify which companies the government had called in, but said the national space agency would carry out a feasibility study.

Musk has a warm relationship with Meloni and said last month he would be ready to offer his services to Italy. However, Defence Minister Guido Crosetto denied an agreement had been sealed.

Starlink, part of Musk's SpaceX aerospace business, has 6,700 active satellites in low earth orbit. A source told Reuters that Italy was considering a five-year deal with the company worth 1.5 billion euros ($1.57 billion).

($1 = 0.9584 euros)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
Japan Pharma Giant Takeda's Anti-Seizure Treatment Flunks In Two Late-Stage Studies
Jun 17, 2024
Monday, Takeda Pharmaceutical Co Ltd ( TAK ) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935). SKYLINE (TAK-935-3001) study evaluated soticlestat plus standard of care versus placebo plus standard of care in patients with refractory Dravet syndrome. Soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency compared to placebo...
Grifols' Biotest Gets FDA Approval for Yimmugo
Grifols' Biotest Gets FDA Approval for Yimmugo
Jun 17, 2024
08:41 AM EDT, 06/17/2024 (MT Newswires) -- Grifols ( GRFS ) said Monday its subsidiary Biotest received approval from the US Food and Drug Administration for Yimmugo, an antibody injection, to treat primary immunodeficiencies. Yimmugo is Biotest's first US-approved medicine and was developed using the company's new Next Level production facility, Grifols ( GRFS ) said. Price: 7.07, Change: +0.07,...
Xali Gold Commences Drilling at El Oro Tailings Project in Mexico
Xali Gold Commences Drilling at El Oro Tailings Project in Mexico
Jun 17, 2024
08:43 AM EDT, 06/17/2024 (MT Newswires) -- Xali Gold ( CGDXF ) said on Monday that it has initiated a 20-hole sonic drill program at the Mexican Mine Tailings Reprocessing Project at El Oro in Mexico. Once production begins, Kappes, Cassiday & Associates will pay Xali Gold ( CGDXF ) a gross royalty equal to 4% of the sales income...
Qiagen Targets 7% Annual Sales Growth Through 2028
Qiagen Targets 7% Annual Sales Growth Through 2028
Jun 17, 2024
08:41 AM EDT, 06/17/2024 (MT Newswires) -- Qiagen ( QGEN ) said Monday it aims to achieve 7% annual sales growth until 2028 and targets a 31% adjusted operating income margin in 2028. The diagnostic services provider said it plans to streamline operations by focusing on key products like its PCR-based genetic testing machines, diagnostic tests for cancer and infectious...
Copyright 2023-2026 - www.financetom.com All Rights Reserved